A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]

PHASE3CompletedINTERVENTIONAL
Enrollment

596

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Crohn's Disease
Interventions
BIOLOGICAL

Certolizumab Pegol (CDP870)

Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Week 2, and every 4 weeks thereafter until Week 362. Up to 84 months of therapy in this study.

Trial Locations (206)

Unknown

45102, Birmingham

45028, Huntsville

45144, Tucson

45095, Orange

45006, San Diego

45131, San Diego

45130, Colorado Springs

45094, Gainesville

45029, Jacksonville

45087, Miami

45085, Plantation

45143, Atlanta

45064, Savannah

45138, Columbus

45111, Louisville

45105, Annapolis

45033, Chevy Chase

45013, Laurel

45057, Plymouth

45108, Jefferson City

45031, Lincoln

45035, Berlin

45124, Florham Park

45018, New Brunswick

45009, Great Neck

45070, New York

45117, Rochester

45003, Raleigh

45040, Winston-Salem

45081, Cincinnati

45091, Cincinnati

45054, Dayton

45039, Oklahoma City

45041, Tulsa

45048, Portland

45084, Chattanooga

45113, Germantown

45071, Nashville

45119, Nashville

45022, Houston

45073, San Antonio

45020, Salt Lake City

45139, Salt Lake City

45052, South Ogden

45078, Christiansburg

45109, Norfolk

45135, Tacoma

11001, Adelaide

11016, Ballarat

11011, Bankstown

11007, Box Hill

11013, Frankston

11010, Fremantle

11015, Garran

11017, Herston

11014, Lauceston

11003, Melbourne

11004, Melbourne

11005, New Lambton

11018, Newtown

11012, Parkville

46005, Graz

46006, Linz

46002, Vienna

12001, Minsk

12003, Minsk

12002, Vitebsk

13004, Brussels

13001, Ghent

13002, Liège

15001, Sofia

15002, Sofia

16014, Halifax

16021, Ottawa

16013, Toronto

16001, Vancouver

16010, Vancouver

18003, Brno

18011, České Budějovice

18006, Hradek Kralove

18009, Mělník

18007, Olomouc

18008, Olomouc

18010, Pardubice

18005, Plzen - Lochotin

18002, Prague

18004, Prague

18012, Prague

19004, Aalborg

19002, Aarhus

19008, Copenhagen

19009, Copenhagen

19001, Glostrup Municipality

19010, Herlev

19007, Hvidovre

19005, Odense C

20001, Tallinn

20002, Tartu

48001, Tbilisi

22002, Berlin

22006, Berlin

22009, Berlin

22021, Cologne

22026, Dresden

22013, Göttingen

22017, Hanover

22015, Kiel

22024, Leipzig

22003, Magdeburg

22001, Minden

22008, Münster

22005, Wilhelmshaven

23002, Shatin

24002, Budapest

24012, Budapest

24015, Budapest

24001, Debrecen

24014, Dunaújváros

24010, Győr

24005, Gyula

24009, Pécs

24008, Szeged

24011, Szekszárd

24007, Veszprém

26004, Beersheba

26007, Haifa

26006, Jerusalem

27002, Bologna

27001, Milan

27004, Palermo

27006, Roma

27007, Roma

28001, Riga

28003, Riga

29001, Kaunas

31002, Auckland

31001, Christchurch

31005, Hamilton

31003, Tauranga

31004, Tauranga

32009, Hamar

32001, Haugesund

32005, Oslo

32008, Oslo

32004, Tromsø

33022, Bialystok

33004, Bydgoszcz

33002, Krakow

33010, Krakow

33011, Lodz

33012, Lodz

33019, Lublin

33020, Opole

33003, Sopot

33013, Szczecin

33001, Warsaw

33007, Warsaw

33009, Warsaw

33016, Warsaw

33006, Wroclaw

33021, Wroclaw

34017, Lipetsk

34006, Moscow

34015, Moscow

34016, Nizhny Novgorod

34001, Saint Petersburg

34005, Saint Petersburg

34007, Saint Petersburg

34013, Saint Petersburg

34008, Volgograd

35001, Belgrade

35002, Belgrade

35004, Belgrade

35005, Belgrade

35003, Niš

36001, Singapore

36002, Singapore

38001, Celje

38003, Ljubljana

38004, Novo Mesto

39003, Cape Town

39016, Cape Town

39017, Cape Town

39011, Durban

39012, Goodwood

39002, Johannesburg

39007, Johannesburg

39010, Johannesburg

39013, Johannesburg

39008, Midrand

39004, Port Elizabeth

39006, Pretoria

39014, Pretoria

39019, Pretoria

40009, Barcelona

41001, Stockholm

41004, Stockholm

41002, Umeå

43005, Crimean Autonomy

43002, Dniepropetrovsk

43008, Dniepropetrovsk

43004, Donetsk

43001, Kharkiv

43007, Kiev

43003, Lviv

43006, Odesa

All Listed Sponsors
lead

UCB Pharma SA

INDUSTRY

NCT00160524 - A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] | Biotech Hunter | Biotech Hunter